RZLT
Rezolute, Inc. Common Stock (NV)
stockNASDAQ
rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.18 | 2026-09-28 | -4.31% | -1.206 |
| 1M | 4.58 | 2026-09-04 | -12.66% | 0.459 |
| 3M | 4.93 | 2026-07-06 | -18.86% | 1.144 |
| 6M | 3.26 | 2026-04-06 | +22.70% | 1.352 |
| 1Y | 9.10 | 2025-10-03 | -56.04% | 0.935 |
| 2Y | 4.93 | 2024-10-04 | -18.86% | — |
| 5Y | 7.30 | 2021-10-04 | -45.20% | 0.788 |
Rezolute, Inc. Common Stock (NV) (NASDAQ:RZLT) stock price today is $4.00, and today's volume is 1,646,388. RZLT is down 1.720% today. The 30 day average volume is 1.62M. RZLT market cap is $386.89M with 96.72M shares outstanding.